Low-dose Enalapril Reduces Angiotensin II and Attenuates Diabetic-induced Cardiac and Autonomic Dysfunctions


Autoria(s): Malfitano, Christiane; De Angelis, Katia; Fernandes, Tiago; Wichi, Rogerio Brandao; Rosa, Kaleizu; Pazzine, Mariana; Mostarda, Cristiano; Ronchi, Fernanda Aparecida; de Oliveira, Edilamar Menezes; Casarini, Dulce Elena; Irigoyen, Maria-Claudia
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

Activation of renin-angiotensin system has been linked to cardiovascular and autonomic dysfunctions in diabetes. Experiments were performed to investigate the effects of angiotensin-converting enzyme inhibitor (ACEI), enalapril, on cardiac and autonomic functions in diabetic rats. Diabetes was induced by streptozotocin (50 mg/kg), and rats were treated with enalapril (1 mg.kg(-1).d(-1)). After 30 days, evaluations were performed in control, diabetic, and enalapril-treated groups. Cardiac function was evaluated by echocardiography and through cannulation of the left ventricle (at baseline and in response to volume overload). Heart rate and systolic blood pressure variabilities were evaluated in the time and frequency domains. Streptozotocin rats had left ventricular systolic and diastolic dysfunctions, expressed by reduced ejection fraction and increased isovolumic relaxation time. The ACEI prevented these changes, improved diastolic cardiac responses to volume overload and total power of heart rate variability, reduced the ACE1 activity and protein expression and cardiac angiotensin (Ang) II levels, and increased angiotensin-converting enzyme 2 activity, despite unchanged blood pressure. Correlations were obtained between Ang II content with systolic and diastolic functions and heart rate variability. These findings provide evidence that the low-dose ACEI prevents autonomic and cardiac dysfunctions induced by diabetes without changing blood pressure and associated with reduced cardiac Ang II and increased angiotensin-converting enzyme 2 activity.

PNPD-CAPES

PNPDCAPES

CNPq-PQ

CNPqPQ

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-SP (FAPESP) [04/04283-8, 07/57595-5]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo SP (FAPESP)

Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)

Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)

Fundacao Zerbini, Sao Paulo-SP

Fundacao Zerbini, Sao PauloSP

Identificador

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, PHILADELPHIA, v. 59, n. 1, supl. 1, Part 1, pp. 58-65, JAN, 2012

0160-2446

http://www.producao.usp.br/handle/BDPI/41854

10.1097/FJC.0b013e3182354776

http://dx.doi.org/10.1097/FJC.0b013e3182354776

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #ANGIOTENSIN-CONVERTING ENZYME INHIBITION #DIABETES CARDIAC FUNCTION #AUTONOMIC MODULATION #ANGIOTENSIN II #HEART-RATE-VARIABILITY #CONVERTING-ENZYME-INHIBITION #LEFT-VENTRICULAR HYPERTROPHY #SPECTRAL-ANALYSIS #AT1A RECEPTORS #SYSTEM #RATS #BRADYKININ #MELLITUS #FAILURE #CARDIAC & CARDIOVASCULAR SYSTEMS #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion